HighTower Advisors
TVTX icon

HighTower Advisors’s Travere Therapeutics TVTX Stock Holding History

HighTower Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.56M Buy
+26,577
New +$1.62M ﹤0.01% 1947
2026
Q1 		– Sell
-5,753
Closed -$220K – 3945
2025
Q4 		$220K Buy
+5,753
New +$187K ﹤0.01% 3293

Other funds holding TVTX

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Stephens Investment Management Group
Stephens Investment Management Group Houston, Texas $9.29B AUM 41.16% 1-Year Est. Return
Emerald Advisers
Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

HighTower Advisors's TVTX Position: Q3 2026 in Review

HighTower Advisors opened a new position in Travere Therapeutics (TVTX) in Q3 2026: 26,577 shares worth $1.56M. The stake represents ﹤0.01% of the portfolio and ranks #1947 among its holdings. This is a return to the name: HighTower Advisors previously reported a position in TVTX as recently as Q4 2025.

HighTower Advisors first reported a position in TVTX in Q4 2025 and has held it in 2 quarters since. 251 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.

  • HighTower Advisors held 26,577 shares of Travere Therapeutics worth $1.56M as of Q3 2026.
  • Travere Therapeutics was a new HighTower Advisors position in Q3 2026.
  • Travere Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q3 2026, its #1947 holding.
  • HighTower Advisors first reported a position in Travere Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 251 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.

Based on HighTower Advisors's 13F filing for Q3 2026, filed 10 Nov 2026.